Cleveland BioLabs Profit Margin

Cleveland BioLabs (CBLI) currently reports a profit margin of -6043.51% as of June 2021. That compares with -246.62% in the prior-year period — down 2350.5% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Cleveland BioLabs's profit margin history and peer comparisons.

Cleveland BioLabs's profit margin decreased from -246.62% to -6043.51% — a 2350.5% year-over-year decrease (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cleveland BioLabs's profit margin of -6043.51% is lower than the Healthcare sector average of 13.89%. That is roughly 43609.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cleveland BioLabs's current -6043.51% should be judged against Healthcare norms (sector average: 13.89%) and against CBLI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -6043.51%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Cleveland BioLabs, and consider following CBLI for alerts when major investors trade the stock.